Chiesi Drug Patent Portfolio
Chiesi owns 12 orange book drugs protected by 63 US patents with Zyflo Cr having the least patent protection, holding only 1 patent. And Mycapssa with maximum patent protection, holding 14 patents. Given below is the list of Chiesi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141457 | Oral octreotide therapy and contraceptive methods | 28 Dec, 2040 | Active |
| US11890316 | Oral octreotide therapy and contraceptive methods | 28 Dec, 2040 | Active |
| US11083733 | Betulin-containing birch bark extracts and their formulation | 04 Jan, 2039 | Active |
| US11266660 | Betulin-containing birch bark extracts and their formulation | 04 Jan, 2039 | Active |
| US10780055 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US10940115 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US10940116 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US11357731 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US11458103 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US11723874 | Delayed release deferiprone tablets and methods of using the same | 25 Oct, 2038 | Active |
| US10238709 | Method of treating diseases | 03 Feb, 2036 | Active |
| US10695397 | Method of treating diseases | 03 Feb, 2036 | Active |
| US11052126 | Method of treating diseases | 03 Feb, 2036 | Active |
| US11338011 | Method of treating diseases | 03 Feb, 2036 | Active |
| US11510963 | Method of treating diseases | 03 Feb, 2036 | Active |
| US11857595 | Method of treating diseases | 03 Feb, 2036 | Active |
| US10039780 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | 10 Jul, 2035 | Active |
| US9295687 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | 10 Jul, 2035 | Active |
| US9439921 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | 10 Jul, 2035 | Active |
| US9700575 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | 10 Jul, 2035 | Active |
| US8680052 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | 09 Mar, 2033 | Active |
| US10010537 | Clevidipine emulsion formulations containing antimicrobial agents | 10 Oct, 2031 | Active |
| US11103490 | Clevidipine emulsion formulations containing antimicrobial agents | 10 Oct, 2031 | Active |
| US8658676 | Clevidipine emulsion formulations containing antimicrobial agents | 10 Oct, 2031 | Active |
| US9352041 | Use of an oleogel containing triterpene for healing wounds | 24 Nov, 2030 | Active |
| US9827214 | Use of an oleogel containing triterpene for healing wounds | 24 Nov, 2030 | Active |
| US9427448 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | 10 Nov, 2030 | Active |
| US8703156 | Liquid formulation for deferiprone with palatable taste | 26 Oct, 2029 | Active |
| US11969471 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US11986529 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US8329198 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US8535695 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US9265812 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US9566246 | Pharmaceutical compositions and related methods of delivery | 17 Sep, 2029 | Active |
| US8759316 | Maintenance of platelet inhibition during antiplatelet therapy | 13 May, 2029 | Active |
| US9925265 | Methods of treating or preventing stent thrombosis | 13 May, 2029 | Active |
| US7612102 | Pre-mixed, ready-to-use pharmaceutical compositions | 26 Dec, 2027 | Active |
| US9364564 | Pre-mixed, ready-to-use pharmaceutical compositions | 26 Dec, 2027 | Active |
| US7932268 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | 19 Aug, 2027 | Active |
| US10758616 | Pre-mixed, ready-to-use pharmaceutical compositions | 18 Apr, 2027 | Active |
| US11547758 | Pre-mixed, ready-to-use pharmaceutical compositions | 18 Apr, 2027 | Active |
| US7659291 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions | 18 Apr, 2027 | Active |
| US8455524 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions | 18 Apr, 2027 | Active |
| US8828444 | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel | 21 Jun, 2025 | Active |
| US10016404 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | 07 Mar, 2025 | Expired |
| US10555938 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | 07 Mar, 2025 | Expired |
| US8618135 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | 07 Mar, 2025 | Expired |
| US9265758 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects | 07 Mar, 2025 | Expired |
| US9364470 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects | 07 Mar, 2025 | Expired |
| US9433617 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects | 07 Mar, 2025 | Expired |
| US9861622 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects | 07 Mar, 2025 | Expired |
| US6130208 | Formulation containing a nucleotide analogue | 29 Jun, 2023 | Expired |
| US7696178 | Optimised formulation of tobramycin for aerosolization | 17 Mar, 2023 | Expired |
| US6987094 | Optimized formulation of tobramycin for aerosolization | 22 Sep, 2022 | Expired |
| US7939502 | Optimised formulation of tobramycin for aerosolization | 14 Jun, 2022 | Expired |
| US7049328 | Use for deferiprone | 28 Jun, 2021 | Expired |
| US5856346 | Short-acting dihydropyridines | 05 Jan, 2021 | Expired |
| US5712279 | Inhibitors of microsomal triglyceride transfer protein and method | 21 Feb, 2020 | Expired |
| US6492365 | Microsomal triglyceride transfer protein | 10 Dec, 2019 | Expired |
| US6114313 | Pharmaceutical compositions for freeze drying | 11 Dec, 2018 | Expired |
| US5739152 | Pharmaceutical emulsion | 14 Apr, 2015 | Expired |
| US5739135 | Inhibitors of microsomal triglyceride transfer protein and method | 14 Apr, 2015 | Expired |
| US6183778 | Pharmaceutical tablet capable of liberating one or more drugs at different release rates | 21 Sep, 2013 | Expired |
Latest Legal Activities on Chiesi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chiesi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US11969471 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Jun, 2024 | US8329198 |
|
Email Notification
Critical
| 06 May, 2024 | US11969471 |
| Mail O.P. Petition Decision | 06 May, 2024 | US11969471 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 02 May, 2024 | US11969471 |
| Record Petition Decision of Granted to Make Entity Status large | 01 May, 2024 | US11969471 |
| Recordation of Patent eGrant | 30 Apr, 2024 | US11969471 |
| O.P. Petition Decision | 30 Apr, 2024 | US11969471 |
|
Recordation of Patent Grant Mailed
Critical
| 30 Apr, 2024 | US11969471 |
| Mail Patent eGrant Notification | 30 Apr, 2024 | US11969471 |
|
Email Notification
Critical
| 30 Apr, 2024 | US11969471 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 30 Apr, 2024 | US11969471 |
| Patent eGrant Notification | 30 Apr, 2024 | US11969471 |
|
Email Notification
Critical
| 11 Apr, 2024 | US11969471 |
|
Issue Notification Mailed
Critical
| 10 Apr, 2024 | US11969471 |
Chiesi's Drug Patent Litigations
Chiesi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 01, 2014, against patent number US8455524. The petitioner Sandoz Inc., challenged the validity of this patent, with EKR Therapeutics, LLC as the respondent. Click below to track the latest information on how companies are challenging Chiesi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7049328 | May, 2017 |
Terminated-Settled
(07 Aug, 2018)
| ApoPharma Inc. | Taro |
| US7932268 | August, 2015 |
FWD Entered
(06 Mar, 2017)
| The Trustees of the University of Pennsylvania) | Coalition for Affordable Drugs VIII |
| US8618135 | August, 2015 |
Final Written Decision
(06 Mar, 2017)
| The Trustees of the University of Pennsylvania | COALITION FOR AFFORDABLE DRUGS VIII, LLC |
| US7612102 | October, 2014 |
Terminated-Denied
(24 Apr, 2015)
| EKR Therapeutics, LLC | Sandoz Inc. |
| US7659291 | October, 2014 |
Terminated-Denied
(24 Apr, 2015)
| EKR Therapeutics, LLC | Sandoz Inc. |
| US8455524 | October, 2014 |
Terminated-Denied
(24 Apr, 2015)
| EKR Therapeutics, LLC | Sandoz Inc. |
Chiesi Drug Patents' Oppositions Filed in EPO
Chiesi drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 21, 2013, by Stein, Evan Md Phd. This opposition was filed on patent number EP05724887A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11833207A | Dec, 2015 | Fresenius Kabi Deutschland GmbH | Patent maintained as amended |
| EP05724887A | Aug, 2013 | Stein, Evan MD PhD | Patent maintained as amended |
Chiesi's Family Patents
Chiesi Drug List
Given below is the complete list of Chiesi's drugs and the patents protecting them.
1. Bethkis
Bethkis is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7696178 | Optimised formulation of tobramycin for aerosolization |
17 Mar, 2023
(2 years ago)
| Expired |
| US6987094 | Optimized formulation of tobramycin for aerosolization |
22 Sep, 2022
(2 years ago)
| Expired |
| US7939502 | Optimised formulation of tobramycin for aerosolization |
14 Jun, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bethkis's drug page
2. Cardene In 0.83% Sodium Chloride In Plastic Container
Cardene In 0.83% Sodium Chloride In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612102 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US9364564 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US10758616 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US11547758 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US7659291 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US8455524 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 0.83% Sodium Chloride In Plastic Container's drug page
3. Cardene In 0.86% Sodium Chloride In Plastic Container
Cardene In 0.86% Sodium Chloride In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612102 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US9364564 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US10758616 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US11547758 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US7659291 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US8455524 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 0.86% Sodium Chloride In Plastic Container's drug page
4. Cardene In 4.8% Dextrose In Plastic Container
Cardene In 4.8% Dextrose In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612102 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US9364564 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US10758616 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US11547758 | Pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US7659291 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US8455524 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 4.8% Dextrose In Plastic Container's drug page
5. Cardene In 5.0% Dextrose In Plastic Container
Cardene In 5.0% Dextrose In Plastic Container is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612102 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US9364564 | Pre-mixed, ready-to-use pharmaceutical compositions |
26 Dec, 2027
(2 years from now)
| Active |
| US7659291 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
| US8455524 | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
18 Apr, 2027
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 5.0% Dextrose In Plastic Container's drug page
Explore Our Curated Drug Screens
6. Cleviprex
Cleviprex is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10010537 | Clevidipine emulsion formulations containing antimicrobial agents |
10 Oct, 2031
(6 years from now)
| Active |
| US11103490 | Clevidipine emulsion formulations containing antimicrobial agents |
10 Oct, 2031
(6 years from now)
| Active |
| US8658676 | Clevidipine emulsion formulations containing antimicrobial agents |
10 Oct, 2031
(6 years from now)
| Active |
| US5856346 | Short-acting dihydropyridines |
05 Jan, 2021
(4 years ago)
| Expired |
| US5739152 | Pharmaceutical emulsion |
14 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cleviprex's drug page
7. Ferriprox
Ferriprox is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10780055 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US10940115 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US10940116 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US11357731 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US11458103 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US11723874 | Delayed release deferiprone tablets and methods of using the same |
25 Oct, 2038
(13 years from now)
| Active |
| US8703156 | Liquid formulation for deferiprone with palatable taste |
26 Oct, 2029
(4 years from now)
| Active |
| US7049328 | Use for deferiprone |
28 Jun, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ferriprox's drug page
8. Filsuvez
Filsuvez is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11083733 | Betulin-containing birch bark extracts and their formulation |
04 Jan, 2039
(13 years from now)
| Active |
| US11266660 | Betulin-containing birch bark extracts and their formulation |
04 Jan, 2039
(13 years from now)
| Active |
| US9352041 | Use of an oleogel containing triterpene for healing wounds |
24 Nov, 2030
(5 years from now)
| Active |
| US9827214 | Use of an oleogel containing triterpene for healing wounds |
24 Nov, 2030
(5 years from now)
| Active |
| US8828444 | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
21 Jun, 2025
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Filsuvez's drug page
9. Juxtapid
Juxtapid is protected by 12 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7932268 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
19 Aug, 2027
(2 years from now)
| Active |
| US10016404 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US10555938 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US8618135 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US9265758 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US9364470 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US9433617 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US9861622 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
07 Mar, 2025
(2 months ago)
| Expired |
| US5712279 | Inhibitors of microsomal triglyceride transfer protein and method |
21 Feb, 2020
(5 years ago)
| Expired |
| US6492365 | Microsomal triglyceride transfer protein |
10 Dec, 2019
(5 years ago)
| Expired |
| US5739135 | Inhibitors of microsomal triglyceride transfer protein and method |
14 Apr, 2015
(10 years ago)
| Expired |
| US5712279 | Inhibitors of microsomal triglyceride transfer protein and method |
21 Feb, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juxtapid's drug page
10. Kengreal
Kengreal is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039780 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
10 Jul, 2035
(10 years from now)
| Active |
| US9295687 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
10 Jul, 2035
(10 years from now)
| Active |
| US9439921 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
10 Jul, 2035
(10 years from now)
| Active |
| US9700575 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
10 Jul, 2035
(10 years from now)
| Active |
| US8680052 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
09 Mar, 2033
(7 years from now)
| Active |
| US9427448 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
10 Nov, 2030
(5 years from now)
| Active |
| US8759316 | Maintenance of platelet inhibition during antiplatelet therapy |
13 May, 2029
(4 years from now)
| Active |
| US9925265 | Methods of treating or preventing stent thrombosis |
13 May, 2029
(4 years from now)
| Active |
| US6130208 | Formulation containing a nucleotide analogue |
29 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6114313 | Pharmaceutical compositions for freeze drying |
11 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kengreal's drug page
11. Mycapssa
Mycapssa is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141457 | Oral octreotide therapy and contraceptive methods |
28 Dec, 2040
(15 years from now)
| Active |
| US11890316 | Oral octreotide therapy and contraceptive methods |
28 Dec, 2040
(15 years from now)
| Active |
| US10238709 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US10695397 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US11052126 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US11338011 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US11510963 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US11857595 | Method of treating diseases |
03 Feb, 2036
(10 years from now)
| Active |
| US11969471 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
| US11986529 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
| US8329198 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
| US8535695 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
| US9265812 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
| US9566246 | Pharmaceutical compositions and related methods of delivery |
17 Sep, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mycapssa's drug page
12. Zyflo Cr
Zyflo Cr is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6183778 | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyflo Cr's drug page